North Dakota

Hospitals

$14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections

Whereas most vaccines under development are designed to protect against one kind of pathogen, NovaDigm Therapeutics thinks a vaccine it’s developing could protect against certain fungal and bacterial infections caused by several species of the fungus Candida. NovaDigm will be able to test its hypothesis thanks to a new 14 million Series B from RusnanoMedInvest, […]

presented by